

117
114

Atty Docket No. 15270J-004743US

PTO FAX NO.: 1-703-308-7751
GROUP 1647 FAX NO.: 1-703-872-9306
TELEPHONE NO.: 1-703-308-1202

**OFFICIAL COMMUNICATION
FOR THE PERSONAL ATTENTION OF
EXAMINER Unassigned**

CERTIFICATION OF FACSIMILE TRANSMISSION

I hereby certify that the following documents in re Application of SCHENK, Dale B., Application No. 09/724,319, filed November 27, 2000 for PREVENTION AND TREATMENT OF AMYLOIDOGENIC DISEASE are being facsimile transmitted to the Patent and Trademark Office on the date shown below.

Document(s) Attached

1. Response (2 pages)
2. Postcard (1 page)
3. Copy of Notice to Comply with Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures (2 pages)

Number of pages being transmitted, including this page: 6

Dated: November 13, 2001


Rosemarie L. Celli, Reg. No. 42,397

***PLEASE CONFIRM RECEIPT OF THIS PAPER BY
RETURN FACSIMILE AT (415) 576-0300***

TOWNSEND and TOWNSEND and CREW LLP
Two Embarcadero Center, 8th Floor
San Francisco, CA 94111-3834
Telephone: 650-326-2400
Fax: 650-326-2422

BEST AVAILABLE COPY

I hereby certify that this correspondence is being facsimile transmitted to
the U.S. Patent and Trademark Office:
Fax No.: 1-703-308-7751
- & -
Fax No.: 1-703-872-9306

On November 13, 2001

TOWNSEND and TOWNSEND and CREW LLP

By: Rosemarie L. Celli, Reg. No. 42,397

Signature: Rosemarie L. Celli

PATENT

Attorney Docket No.: 15270J-004743US
Client Ref. No.: 209-US-CIP5C3

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

SCHENK, Dale B.

Application No.: 09/724,319

Filed: November 27, 2000

For: PREVENTION AND TREATMENT
OF AMYLOIDOGENIC DISEASE

Examiner: Unassigned

Art Unit: 1647

RESPONSE TO NOTICE TO COMPLY
WITH REQUIREMENTS FOR PATENT
APPLICATIONS CONTAINING
NUCLEOTIDE SEQUENCE AND/OR
AMINO ACID SEQUENCE
DISCLOSURES

Assistant Commissioner for Patents
Washington, D.C. 20231

BEST AVAILABLE COPY

Sir:

This paper is submitted in response to the Notice to Comply with
Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino
Acid Sequence Disclosures September 10, 2001.

REMARKS

The Office Action mailed September 10, 2001 is a Notice to Comply with
Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino
Acid Sequence Disclosures. The USPTO received the following papers, as evidenced by

SCHENK, Dale B.
Application No.: 09/724,319
Page 2

PATENT


the attached self-addressed postcard bearing the PTO OIPE "Office Date" of August 27 2001:

1. Transmittal Form (PTO/SB/21) (1 page);
2. Communication Under 37 CFR §§ 1.821-1.825 and Preliminary Amendment (6 pps) w/attached paper copy of Sequence Listing (2 pps);
3. Request to Reference Previously Filed Identical Computer Readable Copy According to 37 CFR 1.821(e) (2 pps); and,
4. Return Receipt Postcard.

In view of the foregoing, Applicants believe the requirements to comply with the Notice to Comply with Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures September 10, 2001. Applicant believes that no fee is required for submission of this Amendment. However, if a fee is required, the Commissioner is authorized to charge such fee to Deposit Account No. 20-1430. Please charge any additional fees or credit any overpayment to the above-noted Deposit Account.

If the Examiner believes a telephone conference would expedite prosecution of this application, please telephone the undersigned at 650-326-2400.


Respectfully submitted,


Rosemarie L. Celli

Reg. No. 42,397

TOWNSEND and TOWNSEND and CREW LLP
Two Embarcadero Center, 8th Floor
San Francisco, California 94111-3834
Tel: (415) 576-0200
Fax: (415) 576-0300
RLC
PA 3183632 v1

BEST AVAILABLE COPY



LAW OFFICES
TOWNSEND AND TOWNSEND AND CREW LLP
Two Embarcadero Center, Eighth Floor
San Francisco, California 94111-3834

BEST AVAILABLE COPY

APPLICANTS: Dale B. Schenk

TITLE: PREVENTION AND TREATMENT OF AMYLOIDOGENIC DISEASE
Application No.: 09/774,319 Filed: 11/27/2000

Kindly stamp the date received to acknowledge receipt of the below-identified documents and return to addressee.

- 1) Transmittal Form PTO/SB/21 (1 p);
2) Communication Under 37 CFR §1.825 and Preliminary Amendment (6 pps)
w/attached paper copy of Sequence Listing (2 pps);
3) Request to Reference Previously Filed Identical Computer Readable Copy According to 37
CFR 1.821(e) (2 pps); and,
4) Return Receipt Postcard.

O I P E

Date Mailed: August 20, 2001 Via: First Class Mail
R1C:wca Attorney Docket No.: 15270J-004743US
PA 3165189 v1





UNITED STATES PATENT AND TRADEMARK OFFICE

COMMISSIONER FOR PATENTS
 UNITED STATES PATENT AND TRADEMARK OFFICE
 WASHINGTON, D.C. 20231
[www.uspto.gov](http://uspto.gov)

APPLICATION NUMBER	FILING/RECEIPT DATE	FIRST NAMED APPLICANT	ATTORNEY DOCKET NUMBER
09/724,319	11/27/2000	Date B. Schenk	15270J-004743US

CONFIRMATION NO. 6653

20350
 TOWNSEND AND TOWNSEND AND CREW
 TWO EMBARCADERO CENTER
 EIGHTH FLOOR
 SAN FRANCISCO, CA 94111-3834

FORMALITIES LETTER



OC0000000066534024*

Date Mailed: 09/10/2001

**NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS
 CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE
 DISCLOSURES**

Applicant is given **TWO MONTHS FROM THE DATE OF THIS NOTICE** within which to file the items indicated below to avoid abandonment. Extensions of time may be obtained under the provisions of 37 CFR 1.136(a).

- This application clearly fails to comply with the requirements of 37 C.F.R. 1.821-1.825. Applicant's attention is directed to the final rulemaking notice published at 55 FR 18230 (May 1, 1990), and 1114 OG 29 (May 15, 1990). If the effective filing date is on or after July 1, 1998, see the final rulemaking notice published at 63 FR 29620 (June 1, 1998) and 1211 OG 82 (June 23, 1998). If the effective filing date is on or after September 8, 2000, see the final rulemaking notice published in the Federal Register at 65 FR 54604 (September 8, 2000) and 1238 OG 145 (September 19, 2000). Applicant must provide an initial computer readable form (CRF) copy of the "Sequence Listing", an initial paper or compact disc copy of the "Sequence Listing", as well as an amendment directing its entry into the application. Applicant must also provide a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d). If applicant desires the sequence listing in the instant application to be identical with that of another application on file in the U.S. Patent and Trademark Office, such request in accordance with 37 CFR 1.821(e) may be submitted in lieu of a new CRF.

For questions regarding compliance to these requirements, please contact:

- For Rules Interpretation, call (703) 308-4216
- To Purchase PatentIn Software, call (703) 306-2600
- For PatentIn Software Program Help, call (703) 306-4119 or e-mail at patin21help@uspto.gov or patin3help@uspto.gov

*A copy of this notice **MUST** be returned with the reply.*

BEST AVAILABLE COPY

NOV. 13, 2001 5:34PM TOWNSEND&TOWNSEND

NO. 260 P. 6/6
Page 2 of 2

J. Parker
Customer Service Center
Initial Patent Examination Division (703) 308-1202
PART 2 - COPY TO BE RETURNED WITH RESPONSE

BEST AVAILABLE COPY